At SCAI 2024, Dr Azeem Latib presented an update on the DurAVR® THV First-in-Human Study, including consistent hemodynamics and excellent safety profile through 1-year post-implantation.

Learn about:

• Study design of the DurAVR® THV First-in-Human (FIH) study.
• 1-year hemodynamic and safety results from the FIH study.
• 2D Flow CMR data from the DurAVR® FIH study demonstrating restoration of normal aortic flow.